ACC 2016: Recent Therapeutic Updates in the Management of Patients with Reduced Ejection Fraction Heart Failure

Program Overview

This CME Program is a Post-Conference Review and Analysis of data presented at the American College of Cardiology 65th Annual Scientific Session and Expo held held in Chicago, Illinois. Expert faculty will highlight newly released data and imperative information for clinical decision making, as it relates to patients with heart failure. The panel will analyze existing prognostic guidelines for patients with reduced and preserved ejection fracture heart failure, and suggest means of proper utilization in practice. Tactics to improve patient education and adherence will also be discussed. Upon completion of this activity, learners will be equipped with the most contemporary information needed to administer optimal individualized treatment plans and improve outcomes in their heart failure patients.

*There is an activity update to this course that briefly reviews the updated guidelines for heart failure treatment!*

Target Audience

Cardiologists, primary care physicians, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with heart failure.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review diagnostic and prognostic guidelines of both reduced and preserved ejection fraction heart failure, including risk stratification and hospitalization.
  2. Analyze clinical trial data pertaining to novel combination therapies in reducing cardiovascular risk in heart failure patients presented at ACC 2016.
  3. Apply patient education and patient-provider communication tactics into personalized treatment plans to improve adherence and overall quality of life in patients with heart failure.


  1. Updated Science and Methods of Risk Stratification in Heart Failure Treatment
  2. Analysis of Clinical Trial Data Pertaining to Novel Combination Treatment Options

    Presented at ACC 2016

  3. Incorporating Patient Education and Communication Strategies into Personalized

    Treatment Plans to Reduce Risk and Improve Quality of Life for Patients with Heart Failure


DunlapMark Dunlap, MD Professor of Medicine Case Western Reserve University Director, Heart Failure Section, Heart and Vascular MetroHealth Medical Center Cleveland, Ohio     JanuzziJames Louis Januzzi, MD Hutter Family Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts       SolomonScott David Solomon, MD Edward Frohlich Distinguished Chair and Professor Harvard Medical School Director, Noninvasive Cardiology Brigham and Women’s Hospital Boston, Massachusetts


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Mark Dunlap, MD Nothing to disclose.
James Louis Januzzi, MDGrant/Research Support: Amgen, Inc.; La Roche Ltd.; Novartis Pharmaceuticals Corporation; Siemens Medical Solutions USA, Inc.; Singulex, Inc.
 Scott David Solomon, MDConsultant/Advisor: Amgen, Inc.; Novartis Pharmaceuticals CorporationGrant/Research Support: Amgen, Inc.; Novartis Pharmaceuticals Corporation

Accreditation StatementTimothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months. AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.


For all CME inquiries or special needs, please contact [email protected] BUTTON